These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 18238737)
1. Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Andress DL; Coyne DW; Kalantar-Zadeh K; Molitch ME; Zangeneh F; Sprague SM Endocr Pract; 2008; 14(1):18-27. PubMed ID: 18238737 [TBL] [Abstract][Full Text] [Related]
2. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. Joy MS; Karagiannis PC; Peyerl FW J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511 [TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA. Sharma A; Marshall TS; Khan SS; Johns B Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232 [TBL] [Abstract][Full Text] [Related]
4. Vitamin D analogues for the management of secondary hyperparathyroidism. Martin KJ; González EA Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385 [TBL] [Abstract][Full Text] [Related]
5. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study. Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308 [TBL] [Abstract][Full Text] [Related]
6. Interventions for metabolic bone disease in children with chronic kidney disease. Hahn D; Hodson EM; Craig JC Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD008327. PubMed ID: 26561037 [TBL] [Abstract][Full Text] [Related]
7. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)]. Lorenzo Sellares V; Torregrosa V Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742 [TBL] [Abstract][Full Text] [Related]
8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
9. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Souqiyyeh MZ; Shaheen FA Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700 [TBL] [Abstract][Full Text] [Related]
10. Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the "U". Cozzolino M; Brandenburg V Clin Nephrol; 2009 Jun; 71(6):593-601. PubMed ID: 19473626 [TBL] [Abstract][Full Text] [Related]
11. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease. Torres PU J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031 [TBL] [Abstract][Full Text] [Related]
12. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Ketteler M; Martin KJ; Wolf M; Amdahl M; Cozzolino M; Goldsmith D; Sharma A; Marx S; Khan S Nephrol Dial Transplant; 2012 Aug; 27(8):3270-8. PubMed ID: 22387567 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study. Roggeri DP; Mazzaferro S; Brancaccio D; Cannella G; Messa P; Di Luca M; Morosetti M; Costanzo AM; di Luzio Paparatti U; Cornago D; Cozzolino M; J Med Econ; 2012; 15(6):1110-7. PubMed ID: 22702445 [TBL] [Abstract][Full Text] [Related]
14. Current treatment options for secondary hyperparathyroidism in patients with stage 3 to 4 chronic kidney disease and vitamin D deficiency. Galassi A; Ciceri P; Porata G; Iatrino R; Boni Brivio G; Fasulo E; Magagnoli L; Stucchi A; Frittoli M; Cara A; Cozzolino M Expert Opin Drug Saf; 2021 Nov; 20(11):1333-1349. PubMed ID: 33993809 [No Abstract] [Full Text] [Related]
15. Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol. Cozzolino M; Galassi A; Gallieni M; Brancaccio D Curr Vasc Pharmacol; 2008 Apr; 6(2):148-53. PubMed ID: 18393917 [TBL] [Abstract][Full Text] [Related]
16. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial. Kovesdy CP; Lu JL; Malakauskas SM; Andress DL; Kalantar-Zadeh K; Ahmadzadeh S Am J Kidney Dis; 2012 Jan; 59(1):58-66. PubMed ID: 21885174 [TBL] [Abstract][Full Text] [Related]
17. Low-dose cholecalciferol supplementation and dual vitamin D therapy in haemodialysis patients. Dusilová-Sulková S; Šafránek R; Vávrová J; Horáček J; Pavlíková L; Palička V Int Urol Nephrol; 2015 Jan; 47(1):169-76. PubMed ID: 25262147 [TBL] [Abstract][Full Text] [Related]
18. [Treatment of secondary hyperparathyroidism in hemodialysed patients--paricalcitol with or without cinacalcet]. Zawierucha J; Małyszko J; Małyszko J; Dryl-Rydzyńska T; Prystacki T; Marcinkowski W Przegl Lek; 2016; 73(4):229-32. PubMed ID: 27526425 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis. Pérez-Ricart A; Galicia-Basart M; Alcalde-Rodrigo M; Segarra-Medrano A; Suñé-Negre JM; Montoro-Ronsano JB PLoS One; 2016; 11(9):e0161527. PubMed ID: 27588942 [TBL] [Abstract][Full Text] [Related]
20. Vitamin D in Chronic Kidney Disease and Dialysis Patients. Jean G; Souberbielle JC; Chazot C Nutrients; 2017 Mar; 9(4):. PubMed ID: 28346348 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]